In a recent transaction, Cary L. Majors, Senior Vice President and President of Healthcare at STERIS plc (NYSE:STE), sold 2,024 ordinary shares of the company. The shares were sold at an average price of $232.13, totaling approximately $469,831. This transaction occurred on May 13, 2024, as reported by a recent SEC filing.
The sale prices for these shares ranged from $231.97 to $232.28, reflecting a weighted average that the executive received for the shares sold. Following the transaction, Majors still retains 11,369 ordinary shares of STERIS plc, valued based on the latest sale price, indicating a continued investment in the company's future.
It's worth noting that of the remaining shares owned by Majors, 9,860 are restricted ordinary shares. These restrictions are set to lapse on various dates ranging from June 3, 2024, to June 2, 2026, according to the details provided in the footnotes of the SEC filing.
STERIS plc, headquartered in Dublin, Ireland, operates in the healthcare sector, specializing in orthopedic, prosthetic, and surgical appliances and supplies. The company has been a key player in the industry, providing a range of products and services for healthcare, pharmaceutical, and other industries.
Investors and market watchers often keep a close eye on insider transactions, such as this one by Majors, for insights into executive confidence and potential future performance of the company. However, these transactions can be influenced by a variety of factors and do not necessarily signal a change in the company's outlook or performance.
The details of the transaction were made public through the mandatory SEC Form 4 filing, which provides transparency into the trading activities of a company's officers, directors, and beneficial owners.
InvestingPro Insights
As STERIS plc (NYSE:STE) continues to make headlines with insider trading activity, real-time data from InvestingPro provides a deeper look into the company's financial health and market performance. With a market capitalization of $23.26 billion and a P/E ratio of 61.13, STERIS stands out in the healthcare sector. The company's growth and profitability metrics are also noteworthy, with a revenue growth of 3.65% over the last twelve months as of Q4 2024 and a gross profit margin of 43.72%.
InvestingPro Tips highlight that STERIS has a perfect Piotroski Score of 9, indicating strong financial health, and has raised its dividend for 13 consecutive years, showcasing a commitment to returning value to shareholders. The company's stock has experienced a significant return over the last week with a 12.33% price total return, reflecting investor optimism.
For investors seeking further insights and tips on STERIS plc, InvestingPro offers additional analysis and metrics. There are 17 more InvestingPro Tips available, which can provide valuable guidance for making informed investment decisions. To explore these tips and more, visit https://www.investing.com/pro/STE and take advantage of the exclusive offer by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.